Aplindore

Drug Profile

Aplindore

Alternative Names: DAB 452; Palindore; SLS-006; WAY-DAB 452

Latest Information Update: 28 Sep 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Ligand Pharmaceuticals; Wyeth
  • Class Antipsychotics; Indoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Parkinson's disease; Restless legs syndrome
  • Discontinued Schizophrenia

Most Recent Events

  • 22 Sep 2016 Aplindore sub-licensed to Seelos Therapeutics
  • 31 Dec 2011 Aplindore is available for licensing as of 31 Dec 2011. http://www.ligand.com/
  • 31 Dec 2009 Suspended - Phase-II for Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top